Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer

Sponsor
Kantonsspital Graubuenden
Study ID
NCT00898794
Status
Unknown

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific
  • Unspecified Childhood Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • coagulation study — OTHER
  • laboratory biomarker analysis — OTHER
  • platelet aggregation test — OTHER

Study Details

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering. PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.

Key Dates

First listed
May 12, 2009
Start date
Oct 31, 2007
Status verified
Jun 2011
Primary completion
May 31, 2009

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

Influence of bevacizumab on platelet aggregation

Related Studies